Cargando…
Nucleoside analogues for the treatment of coronavirus infections
Recent outbreaks of SARS-Coronavirus and MERS-Coronavirus (CoV) have heightened awareness about the lack of vaccines or antiviral compounds approved for prevention or treatment of human or potential zoonotic CoVs. Anti-CoV drug development has long been challenged by the activity of a 3′ to 5′ proof...
Autores principales: | Pruijssers, Andrea J, Denison, Mark R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102703/ https://www.ncbi.nlm.nih.gov/pubmed/31125806 http://dx.doi.org/10.1016/j.coviro.2019.04.002 |
Ejemplares similares
-
Nucleoside analogues for the treatment of animal trypanosomiasis
por: Mabille, Dorien, et al.
Publicado: (2022) -
Nucleoside Analogues as Antibacterial Agents
por: Thomson, Jessica M., et al.
Publicado: (2019) -
Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections
por: Bassetto, Marcella, et al.
Publicado: (2020) -
Aminoribosylated Analogues of Muraymycin Nucleoside Antibiotics
por: Wiegmann, Daniel, et al.
Publicado: (2018) -
Advances in antiviral nucleoside analogues and their prodrugs
por: Seley-Radtke, Katherine, et al.
Publicado: (2018)